Spyre Therapeutics (SYRE) EPS (Weighted Average and Diluted) (2020 - 2026)
Spyre Therapeutics (SYRE) reported EPS (Weighted Average and Diluted) of -$0.74 for Q1 2026, up 96.91% on a YoY basis from -$0.38 in Q1 2025, and little changed quarter-over-quarter from -$0.74 in Q4 2025.
Spyre Therapeutics (SYRE) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Spyre Therapeutics has reported EPS (Weighted Average and Diluted) for 7 years, with the latest figure at -$0.74 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 96.91% year-over-year to -$0.74; the trailing twelve-month figure through Mar 2026 stood at -$7.94 (up 93.45% YoY), and the FY2025 full-year result was -$1.98, up 98.44% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.74, roughly flat from -$0.74 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $40.14 in Q2 2023, with the low at -$564.94 in Q4 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$39.55 across 5 years, with a median of -$4.84 in 2022.
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) soared 14966.67% — and 2024, when it plunged 5009.3%.
- Spyre Therapeutics' EPS (Weighted Average and Diluted) stood at $20.17 in 2022, then sank by 2900.89% to -$564.94 in 2023, then jumped by 94.42% to -$31.53 in 2024, then soared by 97.65% to -$0.74 in 2025, then changed by 0.0% to -$0.74 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.74 (Q1 2026), -$0.74 (Q4 2025), and -$5.97 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Spyre Therapeutics | 6.95 Bn | 6.95 Bn | - | -0.74 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.74 |
| Dec 31, 2025 | -0.74 |
| Sep 30, 2025 | -5.97 |
| Jun 30, 2025 | -0.49 |
| Mar 31, 2025 | -23.95 |
| Dec 31, 2024 | -31.53 |
| Sep 30, 2024 | -42.22 |
| Jun 30, 2024 | -23.61 |
| Mar 31, 2024 | -28.93 |
| Dec 31, 2023 | -564.94 |
| Sep 30, 2023 | 0.86 |
| Jun 30, 2023 | 40.14 |
| Mar 31, 2023 | -4.89 |
| Dec 31, 2022 | 20.17 |
| Sep 30, 2022 | -4.84 |
| Jun 30, 2022 | -0.27 |
| Mar 31, 2022 | -0.37 |
| Dec 31, 2021 | -24.33 |
| Sep 30, 2021 | -0.31 |
| Jun 30, 2021 | -0.10 |